The immunohistochemical assessment of mammary tissue was conducted to examine the alteration of p53 and survival and cellular proliferation proteins like EGFR, ERK, and MMP-1 to inaugurate the signaling pathway by which TMZ demonstrates its anticancer efficacy to counteract the breast cancer. Here, TP53 is linked to breast cancer.